Micardis leads the charge for Boehringer Ingelheim in Japan
This article was originally published in Scrip
Prescription sales at Nippon Boehringer Ingelheim (NBI) in Japan rose by around 6% to ¥173.8 billion ($1.85 billion) at reimbursement prices in calendar 2009, driven by global strategic products including Micardis (telmisartan) and Spiriva (tiotropium).
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.